H1 2026 results: well-managed growth and improved profitability
Filed with Euronext · · 8 pages · English
Summary by 6ix AI
The company reported a significant increase in revenue, driven by acquisitions and organic growth, with annual recurring revenue also showing strong performance. The outlook remains positive, with plans to enhance digital healthcare solutions and capitalize on ongoing market opportunities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Equasens
- Equasens Activates the Business Continuity Plan for its subsidiary ASCA in Chessy (France,77)
- Strong H1 2026 business performance: H1 revenue of €124.5 million (+7.3% on a reported basis) and ARR of €111.1 million at 30 June 2026 (+8.8% vs. 30 June 2025)
- Solide performance commerciale au S1 2026: Chiffre d’affaires semestriel de 124,5 M€ (+7,3% en publié) et ARR de 111,1 M€ au 30 juin 2026 (+8,8% vs. 30 juin 2025)
- Bilan semestriel S1 du contrat de liquidité contracté avec natixis oddo bhf
- Results of the votes on the resolutions submitted to the ordinary annual shareholders' meeting of 25 June 2026
Later from Equasens
- Equasens annonce la publication de son rapport financier semestriel au 30 juin 2026
- Rapport Financier Semestriel 2026
- Sustained growth over the first nine months of 2026: Revenue of €181.8m (+5.6% on a reported basis)
Follow Equasens into a list and get an email when it puts out news.
Follow Equasens